Atypical hemolytic uremic syndrome: 2026 so far

Routine-care cohorts added timing and outcome benchmarks for C5 blockade.

In the months covered, several real-world (non-randomized) cohorts added practical detail on outcomes with C5 inhibitors (complement blockers that target the C5 protein) in aHUS. A US chart review described early and ongoing improvements in blood and kidney measures after starting ravulizumab, including a reported complete TMA response (TMA = thrombotic microangiopathy, small-vessel clotting with blood cell damage) in 68% by 12 months; the study was descriptive, had missing data and no comparison group, and could not fully distinguish which patients had purely complement-driven disease. Pediatric and mixed-age observational reports of eculizumab (including an eculizumab biosimilar, a highly similar version of a biologic drug) also described frequent platelet normalization and few new TMA episodes during follow-up, while kidney recovery was less consistent and often lagged behind blood marker stabilization. This mainly helps set expectations based on what has been seen in routine care, without showing which drug or approach works better than another.

Research covered in: February 2026, March 2026, April 2026, June 2026

Withdrawal studies clarified who relapsed and how monitoring enabled restart.

January and March both described a UK prospective withdrawal experience where eculizumab was stopped under close monitoring in stable patients, with most participants remaining relapse-free over two years. Relapses were reported in a minority and clustered among people with identifiable complement dysregulation/complement regulation abnormalities, and rapid restart of eculizumab within the monitoring plan was described as feasible. The reports also highlighted important limits: selected enrollment (excluding some higher-risk patients) and no randomized comparison against continuing treatment. This adds a clearer framework for why stopping is being studied only in selected situations, and why a person's underlying complement biology may affect relapse risk.

Research covered in: January 2026, March 2026

Registry prevention data and case reports underscored persistent infection risk.

In the months covered, one of the clearest management themes came from registry data on invasive meningococcal disease (a severe bacterial infection) during long-term terminal complement inhibition (blocking the end of the complement system). Combined protection (vaccination plus continuous antibiotics) was linked with fewer infections than either approach alone, while missed boosters, missed antibiotic doses, and occasional antibiotic resistance were documented. Later reports added a single case of meningococcal meningitis (infection of the lining around the brain and spinal cord) occurring during ravulizumab despite vaccination and antibiotic prophylaxis, showing that breakthrough infection can still occur. Separate observational studies in very specific hospital contexts (septic shock; STEMI) reported higher rates of complications such as acute kidney injury and clot-related outcomes among people exposed to C5 inhibitors, without proving causality. These findings help explain why infection-prevention plans and situation-specific safety monitoring stay central parts of care during C5 blockade.

Research covered in: January 2026, May 2026, July 2026, September 2026

Subtype-focused cohorts clarified recovery, relapse timing, and transplant recurrence patterns.

So far in 2026, reports continued to show that aHUS management and outcomes can differ by subtype and setting, especially for anti-factor H antibody disease (an immune form of aHUS) and transplantation. A systematic review in anti-factor H antibody aHUS linked plasma exchange (a procedure that removes and replaces plasma) to faster hematologic remission (blood count recovery) than eculizumab, with similar kidney recovery timing in that review (limited evidence and baseline differences between groups). A pediatric cohort then added longer-term expectations in anti-factor H antibody aHUS treated with abbreviated plasma exchange plus immunosuppression (medicines that dampen the immune system): about half had complete kidney recovery by around two years, relapses often occurred within six months, and time on dialysis independently predicted kidney recovery. In transplant recipients with complement dysregulation, recurrence of post-transplant TMA was reported only in those with complement gene abnormalities (not isolated anti-factor H antibodies) in one cohort. This supports why clinicians often focus on identifying the subtype (antibody vs complement gene abnormality) when discussing relapse or recurrence risk and likely recovery patterns.

Research covered in: May 2026, September 2026

Reports added practical monitoring candidates, from drug levels to severity markers.

In the months covered, monitoring research moved in two directions: adjusting complement blockade and tracking risk in broader TMA populations. Early work suggested it may be feasible to use measured eculizumab levels (with modeling) and ravulizumab trough/complement activity monitoring (checking the lowest drug level before the next dose and how active complement remains) in small cohorts, without proving improved clinical outcomes. Complement activation markers (lab signals that complement is turned on), including sC5b-9 in case reports and Ba in a stem cell transplant TMA study, were repeatedly used as activity signals in specific settings, and a large pediatric first-episode TMA cohort linked early shock/heart failure and mechanical ventilation to higher risk of death or later kidney failure. This points to a growing list of possible tests and early clinical signs being studied to guide how closely someone is followed and how treatment is adjusted, while most of these tools are still exploratory rather than standard.

Research covered in: January 2026, February 2026, August 2026